#longacting

Gilead, Merck team up to develop long-acting HIV drug

Gilead will pay 60% of the development costs for the new HIV treatment being developed with Merck (MSD) American pharmaceutical companies Gilead and Merck announced Monday they have partnered to develop a new HIV therapy that could see daily medications replaced by a treatment that can be taken at longer intervals. The companies aim to combine two of their existing medications to “provide new,…

Newly engineered peptide shows potential as long-acting anti-HIV drug — ScienceDaily

A newly engineered peptide called IBP-CP24 has the potential to be further developed as a long-acting anti-HIV drug that can be used alone or in combination with a broad neutralizing antibody for the treatment and prevention of HIV-1 infection, according to a study published December 5 in the open-access journal PLOS Pathogensby Lu Lu and Shibo Jiang of Fudan University and Lishan Su of the…

Long-acting injectable multi-drug implant shows promise for HIV prevention and treatment — ScienceDaily

A new study published today in Nature Communicationsshows a promising alternative for those who have to take a daily pill regimen. Targeting HIV treatment and prevention, researchers across multiple departments at the University of North Carolina at Chapel Hill collaborated on a seven-year study in animals to make a better injectable drug implant that can combine multiple drugs and is…

Cost savings from same-day long-acting reversible contraception — ScienceDaily

According to a new study by Indiana University School of Medicine doctors, providing adolescents seeking birth control the ability to obtain a long-acting reversible contraceptive on the same day as their clinic visit could lead to significant cost savings for insurance providers.

Published today in the journal JAMA Network Open, the study was the work of three IU School of Medicine faculty —…